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This study assessed the effects of multiplex genetic testing on disease risk
perceptions among 216 healthy adults. Participants, aged 25–40, were
recruited through the Multiplex Initiative, which offered a genetic
susceptibility test for eight common diseases. Participants completed
baseline telephone and web-based surveys prior to making the testing
decision. Three months after the receipt of mailed test results, participants
completed a follow-up telephone survey. Risk perceptions for the eight
diseases were measured at baseline and follow-up, along with beliefs about
genetic causation of those diseases. The main results were: (i) mean risk
perceptions were considerably stable from baseline to follow-up; (ii) the best
predictors of follow-up risk perceptions were the corresponding baseline
perceptions and family history; and (iii) within-individuals, most participants
increased or decreased their risk perceptions for specific diseases in
concordance with the number of risk markers they carry, their family history
and their beliefs about genetic causality of diseases. In conclusion,
participants presented a vigilant approach to the interpretation of genetic test
results, which provides reassurance with regard to a potential inflation of risk
perceptions in the population because of multiplex genetic testing.
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The rapid development and increased availability of
genomic technologies is hastening their clinical trans-
lation. The clinical application of genomic technologies
includes an evolution from traditional genetic testing that
evaluates highly penetrant single disease genes to simul-
taneous testing for multiple common chronic adult-onset
conditions, such as cardiovascular disease, diabetes mel-
litus, and cancer (multiplex tests). Increasing numbers
of multiplex tests providing genetic disease risks are
available to the public through companies providing
direct-to-consumer (DTC) services. Advertising of such
tests was reported to cause little anxiety overall, to
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increase demand for genetic services, but had little effect
on primary care services (1, 2). While a primary assump-
tion underlying the development of genetic tests is that
genetic risk information will benefit users (3), there are
concerns about the efficacy of information provided to
clients within selected DTC models (4, 5), and the actual
impact on individuals receiving multiple disease risks
from a single test is still largely unknown (6). This report
attempts to address the issue by examining a healthy
population’s perceived risk after receiving personal
genetic risk information based on a multiplex test.
Studying individuals’ perceptions of disease risk is
important mainly because it may influence health-related
decisions (7–9), and also because it may relate to psy-
chological distress (10–13). Genetic test results for sin-
gle diseases have been found to have significant impacts
on perceived risk for those diseases (e.g. breast/ovarian
cancer, colon cancer, and Alzheimer’s disease) (10,
14–16), with carriers of risk mutations presenting higher
risk perceptions. However, the impact of multiplex
genetic testing on risk perception remains unknown.
Most people hold misconceptions about the nature and
limitations of genetic tests (17–19), and misinterpret
genetic test results (20, 21). These findingsmay represent
a natural process predicted by fuzzy-trace theory (22),
whereby the default mode of encoding numerical risk
information is by ‘fuzzy’, gist representations, capturing
the global meaning of risks, which is based, among other
factors, on a person’s culture, education, and experience
(23). Research findings support the theory by showing
that genetic risk information is often influenced by
personal beliefs/experiences (24–26), pre-conceived
expectations about the level of one’s risk (27), family
history (28, 29), genetic causal beliefs about diseases
(30, 31), and coherence – perceived understanding of
risk information (32). Emotional reaction to test results
may also have an effect on the interpretation of risk infor-
mation according to the ’risk as feeling’ hypothesis (33).
The aims of this study were: (i) to assess changes in
risk perceptions from baseline to after receiving genetic
test results about lifetime risk for developing multiple
diseases; (ii) to examine the effects of several indicators
of test results on changes in risk perceptions, including
the number of risk markers for specific diseases and
across diseases, the number of diseases for which there
was at least one risk marker, and the extent of increased
risk across diseases; (iii) To examine the effects of
factors found associated with perceived genetic risk for
single diseases on changes in risk perceptions following
a multiplex genetic test. Specifically, we hypothesized
that risk perceptions following multiplex genetic testing
will increase among participants carrying more genetic
risk markers, having a family history of the disease, who
attribute disease to genes, whose understanding of test
results is poorer, andwhose emotional reactions to results
are stronger.
Methods
The Multiplex Initiative (MI) was a collaborative trans-
disciplinary research project of the National Human
Genome Research Institute (Bethesda, MD), the Can-
cer Research Network (http://crn.cancer.gov/) funded by
the National Cancer Institute, the Group Health Coop-
erative (Seattle, WA), and the Henry Ford Health Sys-
tem (Detroit, MI). [The detailed description of methods
is described in Appendix S1, Supporting Information
(34–37)].
Participants
Selection criteria included adults, 25–40 years old,
enrolled in the health plan and not affected with the
conditions assayed through the Multiplex test (i.e. type
2 diabetes, heart disease, high cholesterol, high blood
pressure, osteoporosis, or lung, colon or skin cancer).
The analyses within this manuscript were based upon
216 participants who completed a baseline telephone
assessment, agreed to undergo the Multiplex test,
received test results, talked with a research educator and
completed a 3month follow-up telephone assessment.
Measures
Risk perception was measured at baseline (in a
web-based survey) and in the follow-up using a 7-point
scale for each of the eight diseases in the study. Other
measured variables were: socio-demographic char-
acteristics, family history, genetic attributions, test
results, genetic causal beliefs, perceived understanding
of genetic risk (coherence), emotional reactions to test
results.
Statistical analyses
Comparisons of average risk perceptions across par-
ticipants were carried out using paired sample t-tests.
Regression analyses were used to explain follow-up risk
perceptions of each of the diseases (dependent variables)
by other study variables. To predict changes in risk per-
ceptions from baseline to follow-up, we applied repeated
measures mixed model analyses for each of the eight dis-
eases, using SPSS Version 20 MIXED procedure.
Results
Demographic characteristics of the study population
Eighty two participants (38%) were self-identified as
African American, showing success in recruiting pop-
ulations that are typically underrepresented in genetic
testing studies (38). The remaining characteristics of
the study population include an average age of 35 years
(SD= 4.22), 124 (57%) female, 138 (64%) married or
partnered, and 114 (53%) with at least a college degree.
Test results
Distributions of test results are presented in Fig. 1a–c.
The average number of risk markers per participant was
9.25 [standard deviation (SD)= 1.58], and the range was
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(A) Total number of risk versions (max 15 markers across diseases) (n=216)
(B) Number of diseases for which there was at least one positive marker (n=216)
(C) Percentage of participants having at least one risk marker by diseases
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Fig. 1. (a) Total number of risk versions (max 15 markers across diseases) (n= 216). (b) Number of diseases for which there was at least one positive
marker (n= 216). (c) Percentage of participants having at least one risk marker by diseases.
6–13 risk markers. The average number of diseases for
which there was at least one positive risk marker per
participant was 5.85 (SD= 0.92), and the range was
4–8 diseases. One hundred and ninety five (90%) of
the participants had at least one risk marker for type 2
diabetes, osteoporosis, heart disease and colon cancer.
One hundred and eighty five (86%) participants had at
least one risk marker for high cholesterol, 134 (62%) for
lung cancer, 72 (33%) for high blood pressure, and 43
(20%) for skin cancer.
Risk perceptions: from baseline to follow-up
Changes in risk perceptions from baseline to follow-up
ranged from 86 (41%) participants increasing their per-
ceived risk for type 2 diabetes to 76 (35%) decreas-
ing their perceived risk for skin cancer and heart dis-
ease (Table 1). Comparisons across participants indi-
cated that average risk perceptions remained quite stable
from baseline to follow-up. There were only slight aver-
age increases of risk perceptions for colon cancer and
type 2 diabetes, and a slight average decrease for skin
cancer (Table 1). The rank order of mean risk perceptions
was highly correlated with population risk (prevalence of
the disease in the population) r(Spearman) = 0.71 at base-
line, and r(Spearman) = 0.79 at follow-up.
Regression analyses showed a strong effect of baseline
perceptions on follow-up perceptions of risk for each of
the diseases, explaining between 29% (high cholesterol)
and 48% (skin cancer) of the variance in follow-up risk
perceptions. In addition, reported family history of the
disease had a significant independent effect on follow-up
risk perceptions for colon cancer, lung cancer, heart dis-
ease, osteoporosis, and type 2 diabetes. Given the relative
stability of mean risk perceptions across participants, the
great effect of baseline risk perceptions on follow-up per-
ceptions, and the flux of risk perceptions between base-
line and follow-up within participants, our next analy-
ses intended to discover predictors of within-individuals
changes in risk perceptions from baseline to follow-up.
Prediction of changes in risk perceptions
Time itself had a significant effect only on changes
in risk perceptions for colon cancer, skin cancer and
type 2 diabetes. However, the interaction between time
and test results was significant for skin cancer, lung
cancer, osteoporosis, type 2 diabetes, and high choles-
terol. Probing the interactions by using a computational
approach (39) indicated that risk perceptions decreased
over time only among those who had less genetic mark-
ers for skin cancer (t=−2.69, p= 0.01) and lung cancer
(t=−1.81, p= 0.07), compared to those who had more
markers (skin cancer: t= 0.06; lung cancer: p= 0.95
t= 0.64, p= 0.52). Risk perceptions increased over time
only among those who had more genetic markers for
osteoporosis (t= 2.35, p= 0.02), and type 2 diabetes
(t= 2.68, p= 0.01), compared to those who had less
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Table 1. Perceived risk (range: 1–7) by diseases at baseline and at 3months post-receipt of multiplex results (n=216)
Baseline Follow-up % within subjects changeCumulative lifetime risk (range
of risks based upon absence/
presence of risk markers) Mean SD Mean SD t Increased Decreased
Average risk – 3.25 1.14 3.33 1.07 −1.04 48 43
Colon cancer 5–6% 2.75 1.46 2.93 1.51 −2.01a 37 29
Skin cancer 1–5% 2.95 1.78 2.75 1.67 2.14a 25 35
Lung cancer 6–8% 2.59 1.58 2.51 1.49 0.80 27 33
Heart disease 29–44% 3.81 1.72 3.90 1.65 −0.82 38 35
Osteoporosis 21–51% 2.81 1.63 2.88 1.58 −0.82 33 29
Diabetes 31–64% 3.34 1.84 3.55 1.66 −1.90a 41 31
High blood pressure (51) 86–88% 3.84 1.98 3.95 1.89 −0.99 37 34
High cholesterol b 3.93 1.89 4.12 1.81 −1.58 38 30
SD, standard deviation.
ap< 0.05.
bCholesterol provided no risk numbers, rather simply higher or lower levels of good cholesterol.
markers (osteoporosis: t=−1.09, p= 0.28; type 2 dia-
betes: t= 1.15, p= 0.88). Contrary to findings for the
other diseases, for high cholesterol there were increases
in risk perceptions among those with less risk mark-
ers (t= 2.82, p= 0.01) compared to more risk markers
(t=−0.53, p= 0.59).
For type 2 diabetes and high blood pressure another
significant interaction was found, between time and
reported family history. Risk perceptions increased
over time only among those who reported a family
history of the disease (type 2 diabetes: t= 2.66, p= 0.01;
high blood pressure: t= 2.29, p= 0.02), compared to
those who did not report a family history (type 2 dia-
betes: t= 0.13, p= 0.89; high blood pressure: t=−0.91,
p= 0.36). Perceptions for heart disease and high
cholesterol were also found affected by the interaction
between time and genetic determinism. Risk perceptions
increased significantly among participants with stronger
genetic deterministic beliefs (heart disease: t= 1.94,
p= 0.05; high cholesterol: t= 2.63, p= 0.01), compared
to weaker beliefs (heart disease: t=−0.65, p= 0.51;
high cholesterol: t=−0.33, p= 0.74). Only for lung
cancer, the interaction between time and attributing
the disease to genes was significant. Risk perceptions
decreased among those who attributed lung cancer to
genes (t=−2.03, p= 0.04), compared to those who
had lower genetic attributions for the disease (t= 0.88,
p= 0.38).
Discussion
Our study provides evidence that the receipt of multi-
plex genetic test results had minimal effects on average
disease risk perceptions. This finding is quite surpris-
ing considering that all participants received test results
indicating that they carry at least six risk markers, for at
least four diseases (although the attributable risk asso-
ciated with each marker was low). The small average
group changes in risk perceptions, observed among a
few diseases, were distributed almost evenly between
increases and decreases, consistent with random fluc-
tuations. These findings concur with reports about the
relatively resistant nature of risk perceptions following
receipt of information from a web-based family history
tool that assesses familial risk for six diseases (40).
Notwithstanding the stability of average risk percep-
tions, the majority of participants changed their risk
perceptions from baseline to follow-up, showing both
increases and decreases. These intra-individual changes
were largely consistent with the number of risk mark-
ers carried by participants. Risk perceptions of skin and
lung cancers decreased only among those with less risk
markers, and risk perceptions of osteoporosis, type 2
diabetes and high blood pressure increased only among
those with more risk markers. The direction of changes
in risk perceptions indicates that participants may have
considered the information about population risks as ref-
erences, i.e.: test results induced decreases in risk per-
ceptions for cancers, for which population risks are rela-
tively low, and induced increases in risk perceptions for
the other diseases, for which population risks are rel-
atively high (especially high blood pressure). Surpris-
ingly, risk perceptions of high cholesterol were increased
among those with less risk markers. We can only specu-
late about the reasons for this finding. First, unlike other
diseases, test results for high cholesterol were provided
without risk numbers, rather simply higher or lower lev-
els of good cholesterol, which may have confused partic-
ipants. Secondly, because people tend to see diet as the
most usual cause of raised cholesterol (41), it is possible
that finding out that one does not have a genetic risk for
high cholesterol had diverted attention to dietary attribu-
tions and the elevated risk associated with them. Corre-
spondingly, ‘contradictions in talk about diet’ have been
recently described as a major theme among individuals
who have undergone genetic testing for familial hyper-
cholesterolaemia (FH) where no genetic mutation has
been identified (42). Nonetheless, it is noteworthy that
only disease-specific results, rather than general aggre-
gations of test results, affected risk perceptions.
Regarding predictions of the fuzzy-trace theory
(22, 23), it seems that gist-based impressions of being
at-risk for common-diseases were not based on aggre-
gated test results, but rather, on baseline risk perceptions,
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family history and deterministic genetic beliefs. Because
health-related information that is concordant with exist-
ing beliefs evokes less intensive information processing
and is considered more trustworthy and accurate (43),
a priori beliefs about personal susceptibility to diseases
may be seen as anchors for gist-based impressions of
genetic risk information (44). Likewise, because risk
perception is affected by lay models of inheritance in
the family (45), a family history of diseases may have
considerable impacts on the formation of ‘fuzzy’, gist
representations of risk. These notions are consistent with
previous research showing the importance of baseline
perceptions, family history and genetic attributions on
genetic risk perceptions (27–29, 31).
Contrary to predictions based on the ’risk as feeling’
hypothesis (33), emotional reactions did not moderate
changes in risk perceptions. This may have resulted from
the fact that emotional reactions were generally mild
(a mean of 3 on a scale of 1–7). It could also result
from the fact that risk perceptions were measured in this
study by using a perceived likelihood scale, directing
respondents’ attention to the cognitive component of risk
rather than to ’feeling at risk’ (46). Given the concurrent
measurement of both constructs, we also cannot rule out
the possibility that the mild emotional reactions actually
reflected the relatively small changes in risk perceptions.
The coherence hypothesis (32), whereby individuals who
feel they understand the link between genes and disease
risk would perceive their risk as lower, was also not
supported with regard to changes in risk perceptions in
the context of multiplex testing.
The above findings show that results of a multiplex
genetic test changed individuals’ risk perceptions con-
gruently with findings reported in studies of genetic test-
ing for single diseases (10, 13, 15, 16, 30). This is not
trivial. Unlike testing for a single disease, within a mul-
tiplex setting, participants get much more information,
and may select the type and amount of information they
focus on. In addition, compared to single-disease stud-
ies where participants often are seeking out risk infor-
mation because of interest/concern about a particular
condition, many of the diseases included in a multiplex
test may not have been of interest to the respondents
(47). Finally, while test results for a single disease can
be either favorable or unfavorable, eliciting the inter-
pretation of increased risk as opposite to ‘normal’, in
multiplex genetic testing every individual discovers that
he/she has numerous risk markers distributed along sev-
eral diseases, so that the feedback becomes relatively
undifferentiated. This may result in a ‘dilution effect’,
creating an ‘ordinary’ interpretation of carrying a few
risk markers, and perceiving them as less significant.
These suppositions about differences between single and
multiplex genetic tests were not examined in this study.
They require further research that will compare, by stan-
dard measures, the effects of single genetic test results to
the same results included in a multiplex test.
Finally, while some findings can be generalized across
diseases, such as the prediction of post-test risk percep-
tions by baseline risk perceptions, other findings were
disease specific. This is in line with the observation that
responses to genetic test information may vary across
diseases (20), and points to the need to be more sensitive
to variability among diseases (48).
Limitations
Our study design has limitations that must be mentioned.
The results are limited by sampling biases, with cer-
tain social groups underrepresented despite the robust
population-based recruitment strategies (38). Follow-up
measurements some 3months after disclosure of test
results can also be problematic in view of the evi-
dence that risk perceptions evolve over time lapsed from
testing (11), sometimes depending on decisions about
preventive interventions more than simply on the out-
comes of mutation tests (14). Future studies may be
advised to add a measuring point closer to obtaining test
results, and re-contact participants at more distant time
points post-receipt of results, e.g. 1 year, 3 years, etc., to
re-assess risk perceptions. Other limitations of the study
include the number and identity of diseases examined,
requiring replications of our study with tests for other
common health conditions. It is also worth noting that
assessments of risk perceptions relied solely on a 7-point
scale anchored by extreme judgments between ‘certain
not to happen’ and ‘certain to happen’. These may have
affected the results, given that different measures of risk
perception such as comparative scales or judgments con-
tingent on one’s behavior are not interchangeable (46, 49,
50). We also note that the questions eliciting the pres-
ence or absence of a family history for the disease stud-
ied did not identify the degree of relationship with the
affected relative or the number of affected family mem-
bers. It is possible that effects for family history might
have been stronger if this assessment had been more spe-
cific. Finally, it is important to emphasize that this study
was undertaken within a rigorous web-based educational
setting, limiting the generalizability of our conclusions to
DTC multiplex testing that offer little professional assis-
tance in interpreting results.
Conclusions
All participants in multiplex genetic testing have been
found as carriers of several risk markers for various com-
mon diseases. Despite this, their interpretations of their
risks were quite relaxed. There was no indication of an
average increase in subjective risk perceptions for the
diseases examined. Risk perceptions after receiving test
results were mostly predicted by prior risk perceptions
and by family history of the relevant diseases. However,
at an individual level, most participants have increased
or decreased their risk perceptions for specific diseases
in concurrence with the number of risk markers they car-
ried, their family history and their beliefs about genetic
causality of diseases. These findings indicate that partic-
ipants applied a vigilant approach to the interpretation of
genetic test results and provide reassurance with regard
to a potential inflation of risk perceptions in the popu-
lation because of multiplex genetic testing. It is impor-
tant to note that these results were obtained within a
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program providing extensive educational material both
before and after testing and receiving test results. More
research is required to examine the effects on risk per-
ceptions of other programs, including more genetic tests
and among different populations. In addition, direct com-
parisons between genetic test results received through
multiplex tests vs single disease genetic tests are needed
in order to better understand information processing of
genetic test results.
Supporting Information
The following Supporting information is available for this article:
Appendix S1. Methods in detail.
Additional Supporting information may be found in the online
version of this article.
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